Marco Meglio

Investigators Macarena Hernandez, PhD, and Marc Ribo, MD, provided commentary on positive phase 2a findings assessing ApTOLL in combination with EVT in patients with ischemic stroke.

In comparison with those who underwent additional imaging, patients with large vessel occlusion who directly went to angiography suite had higher mortality, but with no difference in functional outcome.

At the conclusion of the trial, treatment with 0.2 mg/kg of ApTOLL with EVT resulted in reduced brain edema and hemorrhagic transformation, as well as fewer deaths than placebo and 0.05 mg groups.

Nearly two-third of all participants with REM-sleep behavior disorder had mild cognitive impairment level 2 with multi-domain MCI, but particularly attention and memory deficits.

REACT randomly assigned 409 patients—treated with either microsurgical clipping or endovascular coiling aneurysm securing procedures—1:1 to placebo or clazosentan 15 mg/hr, for a 14-day treatment period.

The biosimilar form of natalizumab demonstrated similarities to the FDA-approved form in the primary efficacy end point of cumulative number of new active lesions over 24 weeks.

The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.

During a 12-week treatment period, investigators observed greater reduction in change from baseline in UPDRS score for those on electroacupuncture than just on PD medication alone.

The trial was originally placed on hold because of reported cases of drug-induced liver injury in patients who received the study drug, potentially caused by a preexisting factors related to hepatic dysfunction.

Factoring in the complex nature of the disease, a group of experts provided perspectives on how clinically meaningful benefit should be viewed, stressing the importance of early intervention.

ABATE is an ongoing phase 1b/2 trial that assesses the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060 in individuals with prodromal Alzheimer disease with confirmed amyloid pathology on PET.

In PHOENIX, 664 participants with ALS will be randomly assigned 3:2 to either AMX0035 or placebo for 48-weeks, followed by an optional open-label extension that will continue to assess for efficacy and safety.

A single dose of ubrogepant at its highest FDA-approved strength of 60 mg once daily had no statistically significant effect on atogepant pharmacokinetics.

Treatment with deep brain stimulation resulted in improvements in mean motor scores, reductions levodopa equivalent dosage, and a decrease in neuropsychiatric features.

An exergaming program that spanned 8 weeks showed positive effects for patients with multiple sclerosis both with and without restless legs syndrome.

With a PDUFA date of October 26, 2023, the FDA will review data from the phase 2b VISION-DMD study, in which vamorolone met its primary end point in change in TTSTAND velocity.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.

Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease.

The executive direct of Cure CMD discussed the state of care for patients with congenital muscular dystrophies, the need for new treatments, and the patience with gene therapies.

Data from a cohort of more than 8000 participants suggest that older adults with less optimal sleep duration might benefit from moderate napping for their cognitive functions.

In addition to showing a tolerable safety profile, EQU-001 resulted in reduced IL-17 and IL-1b plasma levels relative to baseline and limited the ability of peripheral mononuclear cells to secrete additional pro-inflammatory cytokines.

After 12 weeks of treatment, almost twice as many patients on eptinezumab reported either “much improved” or “very much improved” than those on placebo, according to Patient Global Impression of Change.

Over a 2-year treatment period, no clear effects of dimethyl fumarate were identified on clinical or MRI outcomes in patients with progressive multiple sclerosis.

Richard Williamson, MD, FAANS, a neurosurgeon at Allegheny Health Network, provided commentary on the explosion of technology in neurosurgery and how exoscopes ease the process.

The new criteria, inclusive of both pediatric and adult patients, advocates for testing for MOG-IgG in appropriate populations, and cautions against testing patients with clinical and radiological features typical of multiple sclerosis.

Data showed that slightly more than half of the patients with NMOSD visited at least 2 neurologists before receiving full diagnosis, and less than 30% reported they were aware of at least 1 nearby specialized NMOSD center.

After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.

Going forward, the company must provide safety and steady-state pharmacokinetic data on the 200 mg dose of IKT-148009, as well as continued measurement of visual acuity and examination of the cornea and lens.

In the combined double-blind and open-label extension periods, plasma neurofilament light levels were lower in those on teriflunomide and were prognostic of relapse or MRI activity.

Mesdopetam showed significant effects on the secondary end point of Unified Dyskinesia Rating Scale, an assessment of involuntary movements associated with long-term treatment with dopaminergic medication.